Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Wednesday told two dramatically different stories about the distance between clinical data and stock price. Sarepta Therapeutics surged 35% after reporting the first clinical results
The big pharma M&A machine keeps running. Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals on Wednesday, adding TERN-701—an oral allosteric BCR::ABL1 inhibitor for
Monday will be remembered as the day T-cell engagers crossed from oncology curiosity into absolute autoimmune conviction. Gilead Sciences and Sanofi, on the exact same
Monday delivered a study in contrasts. Pfizer and Valneva’s Lyme disease vaccine demonstrated 73% efficacy in Phase 3—a clinically meaningful result by any standard—but a
Last week was the most consequential five-day stretch for biotech in 2026 so far. Four FDA approvals, a blockbuster Phase 3 readout, and a $3
Thursday’s headlines underscore a biotech sector caught between transformative clinical milestones and escalating operational risks. BridgeBio delivered highly anticipated Phase 3 FORTIFY data for its
Tuesday delivered a sharp reminder that regulatory reality outranks clinical ambition. Bicycle Therapeutics cut 30% of its workforce and shelved its Nectin-4 drug conjugate—positioned as
The pharma GPU arms race went vertical at NVIDIA GTC 2026. Roche announced 2,176 new Blackwell GPUs—bringing its total footprint to more than 3,500 chips—claiming
The weekend edition captures a biotech landscape at multiple inflection points. Sana Biotechnology reported 14-month follow-up from its first-in-human hypoimmune islet cell transplant at ATTD
Eli Lilly escalated its war on the GLP-1 compounding ecosystem Thursday with a public safety warning that could permanently reshape the regulatory landscape: tirzepatide mixed
